Amgen Inc. $AMGN Stock: Fragasso Financial Advisors Inc Grows Position

Fragasso Financial Advisors Inc lifted its position in Amgen Inc. (NASDAQ:AMGN) by 21.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,185 shares of the medical research company’s stock after acquiring an additional 2,471 shares during the quarter. Fragasso Financial Advisors Inc’s holdings in Amgen were worth $5,885,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of AMGN. Wellington Altus USA Inc. lifted its stake in shares of Amgen by 72.3% during the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after purchasing an additional 34 shares during the last quarter. Tower View Wealth Management LLC raised its holdings in shares of Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after buying an additional 63 shares during the last quarter. Security National Bank of Sioux City Iowa IA acquired a new position in shares of Amgen in the second quarter valued at about $36,000. Evergreen Advisors LLC acquired a new position in Amgen in the 1st quarter worth approximately $37,000. Finally, Steph & Co. purchased a new stake in shares of Amgen in the 3rd quarter valued at $42,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on AMGN shares. HSBC lowered Amgen from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $445.00 to $425.00 in a research report on Thursday, September 10th. Sanford C. Bernstein upped their price objective on shares of Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. Citigroup raised their price target on shares of Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. UBS Group boosted their price target on Amgen from $430.00 to $470.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Barclays raised their price objective on Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen currently has an average rating of “Hold” and an average target price of $387.93.

Insiders Place Their Bets

In other Amgen news, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,642,098.28. The trade was a 23.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 6,222 shares of company stock worth $2,540,926. Corporate insiders own 0.85% of the company’s stock.

Amgen Stock Down 0.6%

Amgen stock traded down $2.59 during mid-day trading on Tuesday, hitting $414.98. The company had a trading volume of 559,026 shares, compared to its average volume of 2,739,187. The business has a fifty day moving average of $413.72 and a 200 day moving average of $372.82. The stock has a market cap of $224.35 billion, a price-to-earnings ratio of 25.78, a PEG ratio of 2.99 and a beta of 0.41. Amgen Inc. has a 1 year low of $288.00 and a 1 year high of $447.03. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The firm had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter in the previous year, the firm posted $6.02 EPS. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts expect that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s payout ratio is currently 62.65%.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.